
Simon Lowth exits AstraZeneca
pharmafile | July 15, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, simon lowth
AstraZeneca’s chief financial officer and executive director Simon Lowth will leave the firm at the end of October.
Lowth has been appointed CFO for the BG Group and will take up his new post in November.
He will retain his responsibilities as CFO and will continue to be a member of the firm’s Board until he leaves the company. AstraZeneca says a search for Lowth’s successor is under way.
Pascal Soriot, chief executive at AstraZeneca, said: “Simon has made a significant and lasting contribution to AstraZeneca’s success, helping put the company on a stronger footing for the future. Personally, I will miss our interactions and I would like to thank him for all his support over the last few months. I know that I speak on behalf of everyone at AstraZeneca in wishing him well in the next chapter of his career.”
The firms adds that Lowth will be paid his base salary and benefits up until the end of October and will receive no payments for the remainder of the notice period. He will not be eligible to receive an annual bonus for 2013 and all outstanding long-term incentive awards made will lapse in accordance with plan rules on termination.
Related Content

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …

Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …






